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Rosiglitazone (RSG), developed for the treatment of type 2 diabetes mellitus, is known to have potent eﬀects on carbohydrate
and lipid metabolism leading to the improvement of insulin sensitivity in target tissues. To further assess the capacity of RSG
to normalize gene expression in insulin-sensitive tissues, we compared groups of 18-day-treated db/db mice with increasing oral
doses of RSG (10, 30, and 100mg/kg/d) with untreated non-diabetic littermates (db/+). For this aim, transcriptional changes
were measured in liver, inguinal adipose tissue (IAT) and soleus muscle using microarrays and real-time PCR. In parallel, targeted
metabolomic assessment of lipids (triglycerides (TGs) and free fatty acids (FFAs)) in plasma and tissues was performed by UPLC-
MS methods. Multivariate analyses revealed a relationship between the diﬀerential gene expressions in liver and liver trioleate
content and between blood glucose levels and a combination of diﬀerentially expressed genes measured in liver, IAT, and muscle.
In summary, we have integrated gene expression and targeted metabolomic data to present a comprehensive overview of RSG-
induced changes in a diabetes mouse model and improved the molecular understanding of how RSG ameliorates diabetes through
its eﬀect on the major insulin-sensitive tissues.
1.Introduction
Type 2 diabetes, also known as non-insulin-dependent
diabetes mellitus, is a chronic disease that aﬀects more than
100 million people worldwide, and its prevalence is soaring
in western countries driven by high-fat diets and sedentary
lifestyles. This pathology is characterized by resistance to the
eﬀects of insulin in peripheral tissues, which is manifested
as reduced insulin-stimulated glucose uptake into skeletal
muscle and adipose tissue, defective insulin-dependent sup-
pression of hepatic glucose output, and reduced insulin
secretion from pancreatic β-cells. Insulin-sensitising drugs,
such as RSG, are widely used in clinical practice to improve
diabetes alteration in glucose metabolism. Thiazolidine-
diones (TZDs) are already known to decrease blood glucose
concentration,toimproveliverandmuscleinsulinsensitivity
[1, 2], and to have signiﬁcant impact on adipose tissue
by inducing adipose diﬀerentiation, lipogenesis, and TG2 PPAR Research
storage [3–6]. The mechanisms of action of TZDs are
mediated through binding and activation of the peroxisome
proliferator-activated receptor γ (PPARγ), a nuclear receptor
that has a regulatory role in lipid metabolism and in cell
diﬀerentiation, particularly in adipocytes [7, 8]. PPARγ is
also expressed in several other tissues, including muscle,
liver, pancreas, heart, and spleen [9]. Among the multiple
actions of TZDs is the normalisation of blood glucose
level, by increasing glucose uptake and decreasing hepatic
glucose production [10]. Moreover, TZDs induce shifts in
systemic lipid proﬁles, with a decrease in FFAs and TGs
levels in the circulation, partly by improving adipocyte
function [11]. Taken together, these eﬀects on carbohydrate
and lipid metabolism are associated with the improvement
of insulin sensitivity of peripheral tissues. However, TZDs
actions are also accompanied by increased adipogenesis and
lipid accumulation in tissues [12, 13]. RSG is a prototype
of the TZD chemical class developed for the treatment of
type 2 diabetes mellitus, and some of these eﬀects are known
to be mediated via gene transcriptional regulation [14–17];
however, the relationship between the RSG-mediated gene
expression regulation in insulin-dependent tissues and the
subsequent physiological changes remains unclear.
Diabetic db/db mice, which have a defect in the leptin
receptor, reproduce many of the metabolic disturbances
present in patients with type II diabetes mellitus, includ-
ing hyperglycaemia, hyperinsulinemia, hyperlipidemia, and
insulin resistance [18]. To address the question of whether
RSG-mediated normalisation of blood and tissue biological
characteristics in treated db/db is accompanied by normal-
ized gene expression in three major insulin-dependent tis-
sues, liver, IAT (inguinal adipose tissue), and skeletal muscle,
we analysed transcriptomic proﬁles of RSG-treated diabetic
mice db/db and compared them with those of untreated non
diabeticlittermatesdb/+.Multivariateanalysiswasthenused
to establish relationships between the RSG-regulated gene
expression proﬁles and metabolomic data obtained from the
insulin-sensitive tissues or blood samples.
This study provides a comprehensive evaluation of
RSG-induced changes in genome-wide expression and its
relationships with RSG-mediated physiological changes in
three main insulin-sensitive tissues known to be involved in
lipid and glucose homeostasis.
2.MaterialsandMethods
2.1. Animals and Treatment. An eight-week old male BKS-
Cg-m+/+ Leprdb/J diabetic (db/db) mice and their nondia-
betic strain (db/+) were obtained from Charles River Lab-
oratories (L’Arbresle, France). Three animals were housed
per cage and acclimatised for 1 week under standard
light (12h light/dark), feeding (db/+: standard laboratory
chow (A03, Safe, France); db/db: 5K52, Safe, France). Mice
were randomly divided into 5 diﬀerent groups (n =
6/group) as follows: vehicle- (1% HEC-) treated nondia-
betic db/+ and diabetic db/db mice (control db/db mice),
and diabetic db/db mice treated orally with the PPARγ
agonist RSG (Syntheval, Caen, France) at 3 separate doses
(10, 30, 100mg/kg/day) for 18 days. Body weight was
measured daily, and blood was collected by orbital sinus
puncture before and after treatment (18h after the last
treatment) to assess glucose levels. All experimental proce-
dures were in accordance with the International European
Ethical Standards (86/609-EEC) and the French National
Committee(decree87/848)forthecareanduseoflaboratory
animals.
2.2. Tissue and Blood Analyses. At the end of treatment,
mice were euthanized by cervical dislocation. Liver, IAT, and
soleus muscle were immediately taken, weighed, ﬂash frozen
in liquid nitrogen, and kept at –80◦C. Blood samples were
drawn into heparin-containing tubes (1.5I.U. heparin for
100μL of blood), and plasma was aliquoted and stored at
4◦C. Blood glucose, Hb, and HbA1c levels were determined
using the automatic analyser COBAS system (Roche, Basel,
Switzerland). FFA and TG Liver and adipose tissues (50mg
aliquots) were extracted with CHCl3. After evaporation,
the organic dry extract was reconstituted in CH3CN/iPrOH
(1/1). Plasma (50µL) was extracted with a mixture of
CHCl3/MeOH (2/1). FFA and TG analyses were performed
by UPLC-MS using a C18 BEH Acquity analytical column,
a gradient of CH3CN, iPrOH, and formic acid (0.1%)
(0.5mL/min, 50◦C), and a 4000 QTRAP (Applied Biosys-
tems, Foster City, CA, USA) and LCT premier (Waters).
2.3. RNA Preparation. Total RNA was prepared from frozen
liver, soleus, and IAT, using Trizol reagent (Invitrogen,
France) and was further puriﬁed by ammonium acetate
precipitation according to standard protocols. Puriﬁed total
RNA concentration and 260/280nm or 260/230nm ratios
were determined using a Nanodrop ND-1000 spectropho-
tometer (Nyxor Biotech, France). Then, total RNA integrity
was checked by microelectrophoresis on acrylamide gel
(Agilent 2100 Bioanalyzer, Agilent, Santa Clara, CA, USA).
2.4. Microarray Hybridization and Data Analysis. Total RNA
(500ng) samples were labelled with cyanine Cy5- or Cy3-
CTPdyesusingAgilentLowRNAInputLinearAmpliﬁcation
Kit (Agilent Technology, PN 5184-3523), according to the
manufacturer’s protocols. Following in vitro transcription,
825ng of test sample (individual db/+: n = 6) or RSG-
treated db/db cRNA were mixed with 825ng of refer-
ence sample (pooled: n = 6db/db cRNA). The samples
were hybridized (dye-swap replicates) on 4 × 44k whole-
Genome 60-mer oligo-microarrays (Agilent technologies,
PN G4122F) for 17 hours at 65◦C. Microarrays were
scanned using a dynamic auto focus microarray scanner
(Agilent technology). Raw data were normalised using local
background subtraction and local Lowess dye normalisation.
Data were analysed using Rosetta Resolver Gene Expression
Analysis System v6.0 (Rosetta Inpharmatics LLC, Seattle,
WA). Dye-swap replicates were precombined before any
statistical analysis. For each group, statistically signiﬁcant
regulated sequences were deﬁned as the sequences whose
expression in the db/+ or in the RSG-treated db/db samples
wasstatisticallydiﬀerentfromtheexpressionintheuntreatedPPAR Research 3
db/db (reference), as calculated by Rosetta error-weighted
model [19]. For this study a P-value < .001 was considered
to be signiﬁcant, and a fold-change value cutoﬀ was ≥| 1.3|.
Ingenuity Pathway Analysis application (Ingenuity Systems,
CA, USA) was used to allow functional interpretation of
the data. Promoter gene sequences were investigated for
the presence of proximal (∼500 bp from initiation site)
PPAR response element (PPRE) in their promoters with
MatInspector (Genomatix; GmbH) [20]. The partial least-
squares (PLSs) projection to latent structure analysis [21]
was performed using Simca-P12 software (Umetrics, Umea,
Sweden).
2.5. Real-Time RT-PCR. Total RNA (1 μg) from each animal
(n = 6/group) and from pooled reference db/db was
reverse transcribed into cDNA using a transcription kit
(Applied Biosystems, PN 4368813). PCR reactions were
then proceeded in microﬂuidic cards using the ABI PRISM
7900HT Sequence Detection System (Applied Biosystems).
Each microﬂuidic card was preloaded with predesigned
TaqmanprobesandprimersforgenesandRNA18Sreference
gene. cDNA (100ng) was mixed with 2X Taqman Universal
PCR master Mix (Applied Biosystems, PN 4324020) and
loaded in each well (n = 3). The following temperature
proﬁle was used: 10min at 94.5◦C, followed by 40 cycles of
97◦C for 30sec and 59.7◦C for 1min. Normalised data with
RNA18Swereanalysedusingthethresholdcycle(Ct)relative
quantiﬁcation method [22], and the ΔΔCt method was
used to compare the amounts of RNA in test and reference
groups.
2.6. Immunocytochemistry. Adipose tissue was ﬁxed in 4%
neutral buﬀered formaldehyde, and cryostat sections of
7μm were prepared. The labelling was performed using a
Discovery XT automat (Ventana Medical Systems, Tucson,
USA). Sections were incubated 1h30 at 37◦Cw i t hA l e x a
ﬂuor 488-conjugated anti-OxPhos Complex IV subunit I
antibody (1/100 dilution, Molecular Probes, PN A21296).
Immunolabelling was visualized and imaged using an LSM
510 confocal microscope (Carl Zeiss SAS, France).
3. Results
3.1. Eﬀects of RSG on Physiological Characteristics. At the
beginning of the experiment the RSG-treated and con-
trol db/db groups of mice were comparably obese and
diabetic. Blood glucose concentrations and body weights
for these two groups were similar and were both sig-
niﬁcantly diﬀerent from db/+ nondiabetic mice (Table 1).
Eighteen days of dose-dependent treatment with RSG
resulted in a reversion of hyperglycaemia. Indeed, a reduc-
tion of blood glucose concentrations and HbA1c were
observed for all RSG doses tested. Blood glucose normal-
isation was obtained from 30mg/kg (0.98 ± 0.12 versus
1.1 ± 0.1g/L in db/+); HbA1c levels from db/db-treated
mice were all signiﬁcantly above the db/+ control mice,
showing only a partial normalisation of this parameter
(Table 1).
3.2. Targeted Metabolomic Assessment of Plasma and Tissue
Lipids. Diabetic db/db mice displayed higher plasma tri-
oleate concentrations than db/+. RSG-treated db/db mice
showed a clear decrease in the levels of the two principal
plasma TGs, trilinoleate and trioleate. When compared to
db/+, TG normalisation was achieved from 10mg/kg RSG
treatment (16.8 ± 6.5v e r s u s2 6 .8 ± 10.2nmol/mL and 6.7 ±
1.6v e r s u s1 1 .8 ± 3.4nmol/mL for trilinoleate and trioleate,
respectively). Plasma FFA concentrations showed a tendency
to be higher in db/db than db/+ mice, but the diﬀerence
remained signiﬁcant only for linoleic acid. RSG treatment
further decreased plasma FFA concentrations compared to
both db/db and db/+, but in this latter case it did not achieve
the signiﬁcance threshold (Table 1).
In the liver of diabetic db/db mice, both TG and FFA
levels reached a higher concentration compared to db/+.
From10mg/kgtheRSGtreatmentofdb/dbfurtherincreased
trioleate and oleic and palmitic acids. In parallel, the liver
weight of RSG-treated db/db mice increased (+86%, +64%,
and +46% at 10, 30, and 100mg/kg RSG, resp.) versus the
control db/db mice.
As expected, IAT weight was higher in both RSG-treated
and control db/db mice compared to the db/+ mice (2.10 ±
0.06 in untreated db/db mice; 1.99 ± 0.11, 2.09 ± 0.13, and
2.16 ± 0.09g in treated db/db mice at 10, 30, and 100mg/kg
RSG, respectively versus 0.17 ± 0.02g in db/+ mice). In
contrast, the TG concentrations relative to adipose tissue
mass in db/+ were markedly higher than in RSG-treated
or untreated db/db. FFA adipose tissue concentrations
remained basically unchanged either between db/db and
db/+ or following RSG treatment except for oleic acid the
levels of which in db/db with or without RSG treatment far
exceeded those of db/+.
Soleus muscle weight was unaltered by both pathology
and treatment (Table 1), although fat accumulation was
observed for control db/db versus RSG-treated db/db during
the soleus muscle dissection.
3.3. Transcriptomic Proﬁle of the Insulin-Sensitive Tissues of
db/+andRSG-Treateddb/db. Changesinglobalgeneexpres-
sionwereassessedinthreeinsulin-sensitive tissues,liver,IAT,
and soleus muscle, involved in glucose and lipid metabolism
usingwhole-mousegenomemicroarrays.Diﬀerencesingene
expression between db/+ or RSG-treated db/db versus the
control db/db group were ﬁltered according to a P-value
< .001 and a fold change ≥| 1.3| (Rosetta error- weighted
model[19]).Onegenecouldberepresentedbydiﬀerentgene
(probes) sequences. Gene alteration between nondiabetic
db/+ versus diabetic db/db mice (see Supplementary Table
1 in material available online at doi: 10.1155/2010/679184)
was determined in the liver (6539 regulated sequences), in
the soleus muscle (7895 regulated sequences), and in the IAT
(13207 regulated sequences). RSG treatment of db/db mice
elicited signiﬁcant changes in the expression of a comparable
number of genes to that observed between db/+ and the
diabetic control db/db reference group, namely in the liver
(5567, 4788, and 4549 regulated sequences at 10, 30, and
100mg/kg RSG, resp.), in the IAT (5710, 9005, and 103354 PPAR Research
Table 1: Animal characteristics, blood and tissue analysis: db/db were compared by Student’s “t”t e s tv e r s u sd b +, #P<. 05; ##P<. 01; ###P<
.001. RSG-treated groups were compared by ANOVA and Dunnett test versus untreated db/db, ∗P<. 05; ∗∗P<. 01; ∗∗∗P<. 001, or versus
db/+, †P<. 05; ††P<. 01; †††P<. 001.n= 6 animals otherwise speciﬁed.
db/db db/+
Parameters (units) Untreated RSG 10mg/kg RSG 30mg/kg RSG 100mg/kg Untreated
Body weight 0d 38.9 ±0.4### 39.4 ±0.63 9 .8 ±0.73 9 .5 ±1.12 4 .6 ±0.7
Body weight (g) 18d 40.6 ±0.7### 46.2 ±0.9
∗∗ 47.8 ±0.6
∗∗∗ 46.8 ±2.1
∗∗ 25.9 ±0.4
Liver weight (g) 1.75 ±0.03### 3.25 ±0.17
∗∗∗ ††† 2.83 ±0.20
∗∗ ††† 2.47 ±0.27
∗† † 1.37 ±0.05
Inguinal Adipose weight (g) 2.09 ±0.06### 1.99 ±0.11
††† 2.09 ±0.13
††† 2.16 ±0.09
††† 0.17 ±0.02
Soleus muscle weight (mg) 6.67 ±1.33 6.00 ±0.85 5.05 ±0.54 .79 ±0.36 6.13 ±1.82
Blood Glucose (mmol/l) 0d 16.9 ±1.3### 16.3 ±1.3
††† 15.8 ±0.9
††† 16.4 ±1.1
††† 5.8 ±0.4
Blood Glucose (mmol/l) 18d 15.1 ±0.9### 8.0 ±0.7
∗∗∗†† 5.4 ±0.6
∗∗∗ 4.1 ±0.5
∗∗∗ 5.1 ±0.5
HbA1c % 7.14 ±0.28### 6.16 ±0.34
††† 5.76 ±0.32
∗∗††† 5.52 ±0.23
∗∗††† 3.61 ±0.13
Plasmatic triglycerides (nmol/mL)
Trilinoleate (n = 3 −5) 49.6 ±2.31 6 .8 ±6.5
∗∗∗ 10.2 ±3.0
∗∗∗ 23.2 ± 5.4
∗∗ 26.8 ±10.2
Trioleate (n = 3 −5) 19.7 ±1.4# 6.7 ±1.6
∗∗∗ 3.2 ±0.9
∗∗∗ 8.0 ±2.5
∗∗∗ 11.8 ±3.4
Plasmatic FFA (nmol/mL)
Palmitic acid 91.8 ±5.57 0 .4 ±7.05 1 .4 ±7.8
∗∗∗ 64.9 ±7.0
∗ 85.9 ±10.5
Linoleic acid 83.8 ±4.5# 70.5 ±6.04 3 .0 ±10.2
∗ 54.5 ±12.76 5 .3 ±4.4
Oleic acid 91.1 ±12.07 2 .1 ±5.43 8 .4 ±12.1
∗∗ 47.4 ±13
∗ 70.2 ±8.9
Liver triglycerides (nmol/g)
Trilinoleate 116 ±24## 76.0 ±21.9
† 43.2 ±8.9
∗ 33.5 ± 4.4
∗∗ 20.0 ±3.9
Trioleate 1033 ±314# 10240 ±1489
∗∗∗ ††† 7746 ±1603
∗∗ ††† 2708 ±846 59 ±13
Liver FFA (nmol/g)
Palmitic acid 481 ±49 583 ±43
†† 573 ±47
† 702 ±67
∗∗ ††† 366 ±13
Linoleic acid 289 ±27# 236 ±7 253 ±17 331 ±46
†† 209 ±11
Oleic acid 484 ±87# 1031 ±110
∗∗ ††† 997 ±82
∗∗ ††† 945 ±148
∗† † † 186 ±18
IAT triglycerides (nmol/g)
Trilinoleate 5965 ±2373 3670 ±1177
†† 5343 ±1542
† 4118 ±674
† 15524 ±4320
Trioleate 7766 ±1962 6515 ±2729 15382 ±5458 11836 ±3059 16016 ±5333
IAT FFA (nmol/g)
Palmitic acid 236 ±61 265 ±24 302 ±67 462 ±36
∗ 424 ±92
Linoleic acid 329 ±53# 328 ±25 454 ±97 570 ±57
∗ 558 ±81
Oleic acid 281 ±48## 310 ±32
† 416 ±110
†† 514 ±56
††† 65 ±10
regulated sequences at 10, 30, and 100mg/kg RSG, resp.),
and in the soleus muscle (3413, 3644, and 3620 regulated
sequences at 10, 30, and 100mg/kg RSG, resp.).
3.4.FunctionalInterpretationoftheChangesinTranscriptomic
Proﬁles. To interpret the biological alteration, diﬀerentially
expressed genes (db/+ or RSG-treated db/db versus control
db/db reference group, Supplemental Table 1) with known
gene symbol (HUGO) were submitted to Ingenuity Pathway
analysis. Each gene symbol was mapped to its corresponding
gene in the Ingenuity Pathways Knowledge database, and
biological functions and diseases were assigned to the
pattern of gene expression. Functions were listed from
most signiﬁcant to least, and the horizontal line shows the
cutoﬀ value for signiﬁcance (P<. 05, adjusted Benjamini-
Hochberg; Supplemental Figure 1). As expected, either in
the nondiabetic db/+ (diabetes eﬀect given as reciprocal
( d b / +v e r s u sd b / d b ) ,s e eb e l o w )o ri nt h eR S G - t r e a t e d
db/db mice, the changes in expression mainly involved
genes related to lipid and carbohydrate metabolism not
only in the liver but also in the IAT and the soleus muscle
(Supplemental Figure 1). Moreover, groups of genes were
also enriched in several functions related to cell signalling,
movement, or development in liver, adipose tissue, and
soleus muscle. These results could be explained by diabetes-
induced morphological and/or growth alteration of hepato-
cytes, adipocytes, and myocytes in db/db mice as well as in
db/db under RSG treatment. However, in the attempt to link
transcriptomic and metabolomic data we focussed our study
on genes involved in lipid and carbohydrate metabolism
and potentially associated with diabetes. This list included
506 gene sequences involved in glycolysis, gluconeogenesis,
TG and FFA metabolism, and pentose phosphate synthesis,
as well as genes involved in mitochondrial functions, that
is, β-oxidation, citrate cycle, and oxidative phosphorylation.
Thereafter, to facilitate direct comparison with RSG treat-
ment eﬀect, we used the reciprocal form of the diabetesPPAR Research 5
Table 2: Model parameters from multivariate analysis (PLS) based on liver, IAT and muscle gene expression. R2X: % of variation of X that
explained Y; R2
Ycum: % of variation of Y explained by the model; Q2
Ycum: % of variation of Y predicted by the model. Cum are for all PLS
components.
PLS component R2X(cum) R2Y(cum) Q2(cum) P-value
Liver
Oleic 275 gene
sequences 1 0.67 0.78 0.76 3.06E-07
Oleic 40-top gene
sequences 1 0.94 0.80 0.80 5.00E-08
Trioleate 275 gene
sequences 2 0.74 0.86 0.80 3.11E-06
Trioleate 40-top
gene sequences 2 0.72 0.89 0.85 2.30E-07
Weight 275 gene
sequences 2 0.77 0.96 0.95 4.92E-11
Weight 40-top
gene sequences 1 0.75 0.96 0.93 1.80E-14
Liver+IAT+Soleus
Glycemia 846 gene
sequences 4 0.71 0.94 0.73 1.00E+00
Glycemia 40-top
gene sequences 3 0.86 0.84 0.68 7.00E-03
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Figure 1: Expression proﬁles of key genes involved in liver glucose and lipid metabolism. Diﬀerentially expressed genes in db/+ (the white
s q u a r e )a sw e l la s1 0( t h eo ﬀ-white square), 30 (the grey square), and 100 (the black square) mg/kg RSG-treated db/db mice were measured
versus untreated db/db and plotted as the mean (% increase/decrease of db/db control) ±SEM (n = 6). NS; P ≥ .001 otherwise P<. 001. (a)
Genesrelatedtoglucosemetabolism:Aldoa,Aldob,aldolase1A,2B;Fbp1,fructosebisphosphatase1;G6pc,glucose-6-phosphatase,catalytic;
Gapdh, glyceraldehyde-3-phosphate dehydrogenase; Pdk4, pyruvate dehydrogenase kinase, isoenzyme 4; Pklr, pyruvate kinase liver and red
blood cell; Slc2a2, solute carrier family 2 (facilitated glucose transporter), member 2. (b) Genes related to FA transport, FA and TG synthesis,
and pentose pathway: Acaca, Acacb, acetyl-Coenzyme A carboxylase alpha, beta; Acly, ATP citrate lyase; Agpat2, Agpat6, 1-acylglycerol-3-
phosphate O-acyltransferase 2, 6; Apoc3, apolipoprotein C-III; Cd36, CD36 antigen; Fabp2, fatty acid-binding protein 2, intestinal; Fabp4,
fatty acid-binding protein 4, adipocyte; Fasn, fatty acid synthase; Gpd1, glycerol-3-phosphate dehydrogenase 1 (soluble); Lpl, lipoprotein
lipase; Mgll, monoglyceride lipase; Pgd, phosphogluconate dehydrogenase; Scd1, stearoyl-Coenzyme A desaturase 1; Taldo1, transaldolase
1; Tkt, transketolase.
eﬀect, that is, untreated nondiabetic db/+ versus diabetic
mice db/db. Consequently, RSG-induced normalisation of
gene expression is deﬁned as genes that were signiﬁcantly
changed by RSG (RSG-treated db/db versus db/db) in the
same direction as nondiabetic (db/+ versus db/db) mice.
3.5. Eﬀect of RSG on the Liver Metabolic-Related mRNA
Expression. In the liver among the 506 gene sequences
276 were diﬀerentially expressed in either db/+ versus
db/db (Supplemental Table 2) or RSG-treated db/db versus
db/db. Supplemental Figure 2(a) displays the microarray6 PPAR Research
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Figure 2: Correlation plot between microarray and qPCR data. Genes involved in (a) liver carbohydrate metabolism, (b) liver FA and TG
metabolism, (c) IAT FA and TG metabolism, and (d) IAT citrate cycle and oxidative phosphorylation. Microarray ratio of diﬀerentially
expressed genes in db/+ and RSG-treated db/db versus untreated db/db mice were plotted on the y-axis and qPCR ratio data on the x-axis.
Correlations were assessed using Pearson’s correlation coeﬃcient (r)a n dP-value <.001.
data overview of diﬀerentially expressed genes between lean
db/+ or RSG-treated mice and the diabetic db/db strain
involved in glucose metabolism. As shown in Figure 1(a),
remarkably, RSG treatment resulted in a partial or complete
normalisation in mRNA expression of genes encoding
for glycolysis/gluconeogenesis key enzymes such as Glut-
2, Gapdh, Pklr or Fbp1, and G6pc. These eﬀects were
particularly pronounced at 100mg/kg of RSG. The only
exception is Pdk4 mRNA expression which is downregulated
in db/+ mice but increased in RSG-treated db/db mice
when compared to the control db/db. Real-time PCR was
used to conﬁrm the diﬀerential expression of genes involved
in glucose metabolism (Supplemental Table 3). Figure 2(a)
shows that microarray ratio measurements were strongly
correlated to that obtained by PCR (r = 0.97; P<. 001;
number of xy pairs = 23).
Contrary to gluconeogenesis-related genes, which
seemed to be normalised by RSG treatment, microarray data
overview shows that a large number of genes involved in
lipid metabolism was regulated in the opposite direction to
db/+ (Supplemental Figures 2(b) and 1(b)). This included
genesthatweredownregulatedindb/+butwereallmarkedly
upregulated in RSG-treated mice when compared to db/db.
For example, at 10mg/kg RSG-mediated upregulation of
genes implicated in lipid metabolism synthesis (Figure 1(b)),
such as the lipid transporters Cd36 (+62%, P<. 001), the
fatty acid binding protein Fabp4 (+870%, P<. 001), the key
enzymes in FFA and TG synthesis such as the ATP citrate
lyase (Acly, +124%, P<. 001), the acetyl-CoA-carboxylase
(Acaca, +87%, P<. 001), the fatty acid synthase (FAS,
+270%, P<. 001), and the stearoyl-Coenzyme A desaturase
(Scd1, +455%, P<. 001) or was involved in the pentosePPAR Research 7
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Figure 3: Two-dimensional representation of diﬀerentially expressed genes involved in IAT mitochondrial and peroxisomal functions.
Ratio for diﬀerentially expressed genes in db/+ and RSG-treated db/db versus untreated db/db were plotted. Each coloured box represents
diﬀerential expression ratio ranging from bright green (lowest) to bright red (highest). Missing value are in grey when P-value ≥ .001. Genes
involvedinmitochondrialtransportofFA,inmitochondrialandperoxisomalβ-oxidationandcitratecycleandinoxidativephosphorylation
were shown.
phosphate pathway such as the transketolase (Tkt, +74%,
P<. 001) and phosphogluconate dehydrogenase (Pgd,
+117%, P<. 001). All these results were conﬁrmed by real-
time qPCR with a very strong correlation (Supplemental
Table 3 and Figure 2(b); r = 0.94, P<. 001; number of xy
pairs = 155). The increased expression of genes encoding
lipogenic enzymes and the pentose phosphate pathway could
account for the increase in liver TG, FFA content, and weight
liver (Table 1).
3.6.EﬀectofRSGonIATMetabolic-RelatedmRNAExpression.
In adipose tissue, among the 506 gene sequences 391
were diﬀerentially expressed in either db/+ versus db/db
or RSG-treated db/db versus db/db (Supplemental Table
2). Numerous upregulated genes in db/+ or RSG-treated
db/db relative to db/db diabetic mice (Supplemental Figure
3a n dFigure 3) potentially stimulate lipid metabolism and
mitochondrial functions.
Contrary to the liver, RSG treatment in IAT regulated
the majority of metabolism-related genes in the same
direction as observed in db/+ mice when compared to
db/db. Indeed, genes involved in glucose metabolism, FFA
and TG metabolism, pentose phosphate synthesis, and
mitochondrial function were upregulated and/or normalised
by RSG-treatment, some of them with a clear dose eﬀect
(Figures 4(a), 4(b), 4(c)). RSG treatment (10–100mg/kg)
partially normalised mRNA expression (Figure 4(a))o ft w o
key genes involved in glucose metabolism such as the glucose
transporter Glut4 (Slc2a4, +45%, P<. 001 in 30mg/kg
RSG group and +114%, P<. 001 in db/+ group) and
the pyruvate dehydrogenase kinase 4 the downregulation of
which stimulates glucose metabolism (Pdk4, 37%, P<. 001
in 30mg/kg RSG group and no change in db/+ group).
On one hand, we observed partial normalisation of genes
encoding FFA or TG metabolic enzymes including Acaca
(+163%, in 30mg/kg RSG group and +474%, in db/+ group,
P<. 001) and Fasn (+240%, in 30mg/kg RSG group and
+674%, in db/+ group, P<. 001) or the pentose phosphate
pathway gene Tkt (+86%, in 30mg/kg RSG group and
+409% in db/+ group, P<. 001) (Figure 4(a)). On the
other hand, for almost all genes involved in mitochondrial
β-oxidation,citratecycle,andoxidativephosphorylation,the
level of upregulated genes observed in RSG-treated mice far
exceeded that of db/+ regulated genes (Figures 4(b), 4(c)).
All these results were validated with qPCR technique with
strong correlation (Supplemental Table 3 and Figure 2(c);
r = 0.83, P<. 001; number of xy pairs = 96; Figure 2(d);
r = 0.80, P<. 001; number of xy pairs = 156).
3.7. Mitochondrial Renewal in db/db IAT Treated with RSG.
T h eg e n ee x p r e s s i o nc h a n g e so b s e r v e di na d i p o s et i s s u e
suggested a mitochondrial dysfunction in db/db diabetic
mice, but the RSG treatment appears to normalise a part
of these alterations. To test whether diabetes and RSG8 PPAR Research
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Figure 4: Expression proﬁles of key genes involved in IAT FA metabolism. Diﬀerentially expressed genes in db/+ (the white square)
as well as 10 (the oﬀ-white square), 30 (the grey square), and 100 (the black square) mg/kg RSG-treated db/db mice were measured
versus untreated db/db and plotted as the mean (% increase/decrease of db/db control) ±SEM (n = 6). NS; P ≥ .001 otherwise
P<. 001. (a) Genes related to FA transport, glucose, FA and TG synthesis and pentose pathway∗: Agpat3, 1-acylglycerol-3-phosphate
O-acyltransferase 3; Dgat1, diacylglycerol O-acyltransferase 1; Slc27a1, solute carrier family 27 (fatty acid transporter), member 1; Slc2a4,
solute carrier family 2 (facilitated glucose transporter), member 4. (b) Genes related to mitochondrial and peroxisomal β-oxidation: Acaa1a,
Acaa1b, acetyl-Coenzyme A acyltransferase 1A, 1B; Acaa2, acetyl-Coenzyme A acyltransferase 2; Acadl, acyl-Coenzyme A dehydrogenase,
long chain; Acadm, acyl-Coenzyme A dehydrogenase, medium chain; Acads, acyl-Coenzyme A dehydrogenase, short chain; Acadvl, acyl-
Coenzyme A dehydrogenase, very long chain; Acox1, acyl-Coenzyme A oxidase 1, palmitoyl; Cpt2, carnitine palmitoyltransferase 2; Crat,
carnitine acetyltransferase; Dci, dodecenoyl-Coenzyme A delta isomerase (3,2 trans-enoyl-Coenzyme A isomerase); Echs1, enoyl-Coenzyme
A hydratase, short chain 1 mitochondrial; Ehhadh, enoyl-Coenzyme A, hydratase/3-hydroxyacyl-Coenzyme A dehydrogenase; Hadhb,
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme A hydratase, beta subunit. (c) Genes related
to citrate metabolism and oxidative phosphorylation: Atp5a1, ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit,
isoform 1; Atp5b, ATP synthase, H+ transporting mitochondrial F1 complex, beta subunit; Cox1, M. musculus mRNA for mitochondrial
gene for subunit I of cytochrome c oxidase; Cs, citrate synthase; Fh1, fumarate hydratase 1; Mdh2, malate dehydrogenase 2, NAD
(mitochondrial); Sdha, succinate dehydrogenase complex, subunit A, ﬂavoprotein (Fp); Sdhb, succinate dehydrogenase complex, subunit
B, iron sulfur (Ip); Sucla2, succinate-Coenzyme A ligase, ADP-forming, beta subunit; Uqcrc1, Uqcrc 2, ubiquinol-cytochrome c reductase
core protein 1, 2; Uqcrfs1, ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1; Uqcrq, ubiquinol-cytochrome c reductase,
complex III subunit VII. ∗gene abbreviations given in Figure 1 were not mentioned.
also aﬀected mitochondrial biogenesis and functioning at
cellular level, the mitochondrial content of adipocytes was
determined by using a monoclonal antibody speciﬁc for
OxPhos Complex IV subunit I (Cox1), a mitochondrial
membrane-bound protein complex. We have compared
controldb/dbversus30mg/kgRSG-treateddb/dbadipocytes
mitochondrial content, to avoid any possible side eﬀects of
the 100mg/kg dose. As shown in Figure 5, signal intensity
was stronger in adipocytes treated with RSG than in
control db/db diabetic mice (P<. 05). These results
conﬁrmed the transcriptional upregulation of Cox1 (+74%;
P<. 001) observed at 30mg/kg dose and suggested that
RSG induced mitochondrial biogenesis in adipocytes, as
previously described [23, 24].
3.8. Eﬀect of RSG on Metabolic-Related mRNA Expression in
Soleus Muscle. In soleus muscle among the 506 regulated
gene sequences 186 were diﬀerentially expressed either in
db/+ versus db/db or RSG-treated db/db versus db/db
(Supplemental Table 2). Soleus muscle plays an important
role in both carbohydrate and FFA metabolism. It is well
established that in obesity there is a dysfunction in the
capacity of skeletal muscles to store glycogen. Also, increasedPPAR Research 9
Untreated db/db mouse
(a)
30mg/kg rosiglitazone treated db/db mouse
(b)
Figure 5: Immunochemical detection in db/db and RSG-treated db/db of the IAT OxPhos complex IV subunit I. IAT from untreated db/db
(a) and from 30mg/kg RSG-treated db/db (b) were isolated, ﬁxed on slide, and stained with anti-OxPhos complex IV subunit I. Nuclei were
identiﬁed with Hoechst 33342.
TG storage is positively correlated with markers of insulin
resistance. Supplemental Figure 4 displayed microarray data
overview of diﬀerentially expressed genes between lean db/+
or RSG-treated db/db mice and the untreated diabetic db/db
involved in glucose and FFA metabolism. Fewer genes were
regulated by RSG treatment in muscle in comparison to the
liver and IAT. However, similarly to the diﬀerential gene
expression observed between the db/+ and db/db diabetic
mice, RSG induced an upregulation of key genes involved in
carbohydrate metabolism such as Pkm2 (+44%, +45%, and
+42% at 10, 30, and 100mg/kg RSG, resp.) and HK1 (+57%,
+60%, and +69%). Moreover, RSG treatment resulted in the
repression of genes involved in lipid transport (Figure 6(a)),
likeCd36(42%,30%,and11%at10,30,and100mg/kgRSG,
resp.)andFabp4(59%,35%,and+30%).RSGalsodecreased
the expression of genes involved in FA and TG metabolism
like Acaca (25%, 40%, and 16% at 10, 30, and 100mg/kg
RSG, resp.) and MgII (32%, 14%, and +33%) (Figure 6(a)).
It is noteworthy that the changes induced in gene expression
by 10mg/kg RSG tended to be most similar to db/+ versus
db/db than the 30 and 100mg/kg doses (see Figure 6(a),
Acaca,Fabp4orMgll).Thistendencyseemedtobespeciﬁcto
soleusmuscleandsuggestspossibletoxicorsecondaryeﬀects
of high RSG concentrations. Taken together, these results
suggest a decrease in FFA uptake and an increase in glucose
utilization in soleus muscle of RSG-treated animals.
3.9. PLS Analysis. Multivariate statistical approach (PLS)
has been applied in order to establish potential rela-
tionships between the changes in transcriptional proﬁle
and metabolic parameters under RSG treatments (Table 1).
This method utilizes a linear regression model on latent
structure to ﬁnd correlations between two data matrices
(X and Y). The signiﬁcant diﬀerentially expressed sequences
(Supplemental Table 2) involved in metabolism were deﬁned
as predictor variables (X) and FFA, TG (tissues and plasma)
and glucose concentrations were deﬁned as observation
variables (Y). The models were retained based on R2
Ycum
(% of explained sum of squares), Q2
Ycum (% of predictive
sum of squares) and P-value. No model based on diﬀerential
gene expression using data from IAT (391 sequences) and
soleus (186 sequences) could be obtained. However, the
predictor variables corresponding to diﬀerentially expressed
sequences in liver (276) enable us to derive signiﬁcant PLS
models regarding the Y variables such as oleic acid and
trioleate tissue concentrations (Table 2) as well as the liver
weight. Figures 7(a), 7(b) show the correlation between the
observed trioleate concentrations or liver weight and the
predicted ones obtained from PLS models built using the
40 best sequence predictors (R2
Ycum = 0.89 and 0.96, resp.).
Among the 40 sequence predictors for liver trioleate concen-
trations and weight, 20 are common. Removing redundancy
among the 20 predictors led to 16 genes from which 13
displayed PPRE in their proximal promoters as determined
by MatInspector from Genomatix suite (see Section 2 and
Supplemental Table 4). An interesting observation is that
using the combination of diﬀerential gene expression from
the three tissues (853 gene sequences) we were able to ﬁnd
a PLS model that made the link between predictor gene
sequences and the blood glucose concentrations. Correlation
between observed and predicted glucose using the 40 best
predictors led to an acceptable model (P = .007 and
R2
Ycum = 0.83; Figure 7(c)) but predictive potency of the
model remained rather weak (Q2
Ycum = 0.68). Among
the 40 predictors 35 belong to the IAT, 4 to the liver,
and 1 to the soleus. A great deal of IAT mRNA- (24/35
sequences) encoded proteins involved in the mitochondrial10 PPAR Research
Table 3: Diﬀerential expression of the 40 best predictor gene sequences from PLS analysis of combined tissues: liver, IAT, and soleus. x:
MatInspector-predicted PPRE.
Tissues Gene
name Function Sequence
description PPRE db/+ RSG 10MK RSG 30MK RSG 100MK
F. C. F. C. F. C. F. C.
S Cyp4a12a Fatty acid
metabolism
cytochrome P450,
family 4, subfamily
a, polypeptide 12a
1.72 1.25 1.27 1.46
TA Dci Fatty acid
metabolism
dodecenoyl-
Coenzyme A delta
isomerase (3,2
trans-enoyl-
Coenzyme A
isomerase)
x 1.51 1.28 1.68 1.85
TA Mcat Fatty acid
metabolism
malonyl CoA: ACP
acyltransferase
(mitochondrial)
1.57 1.29 1.54 1.66
TA Ppargc1b Fatty acid
metabolism
peroxisome
proliferative
activated receptor,
gamma,
coactivator 1 beta
1.63 −1.06 1.37 1.83
TA Ppargc1b Fatty acid
metabolism
peroxisome
proliferative
activated receptor,
gamma,
coactivator 1 beta
2.11 1.10 1.67 2.33
TA Ppargc1b Fatty acid
metabolism
peroxisome
proliferative
activated receptor,
gamma,
coactivator 1 beta
1.41 −1.10 1.30 1.80
TA Dlat Gluconeogenesis
dihydrolipoamide
S-acetyltransferase
(E2 component of
pyruvate
dehydrogenase
complex)
x 1.77 1.49 2.10 2.72
TA Ldhb Gluconeogenesis lactate
dehydrogenase B
1.76 1.07 1.36 1.81
TA Pdhb Gluconeogenesis
pyruvate
dehydrogenase
(lipoamide) beta
2.19 1.69 2.49 3.05
TA Pdhb Gluconeogenesis
pyruvate
dehydrogenase
(lipoamide) beta
2.04 1.65 2.32 2.82
L Pfkfb2 Gluconeogenesis
6-phosphofructo-
2-kinase/fructose-
2,6-biphosphatase
2
x −1.16 −1.72 −1.59 −1.56
L Ppargc1a Gluconeogenesis
peroxisome
proliferative
activated receptor,
gamma,
coactivator 1 alpha
x −1.32 −1.53 −1.61 −1.59
L Ppargc1a Gluconeogenesis
peroxisome
proliferative
activated receptor,
gamma,
coactivator 1 alpha
−1.64 −1.71 −1.75 −1.75PPAR Research 11
Table 3: Continued.
Tissues Gene
name Function Sequence
description PPRE db/+ RSG 10MK RSG 30MK RSG 100MK
TA Atp5h
Mitochondrial
respiratory
chain
ATP synthase, H+
transporting,
mitochondrial F0
complex, subunit d
x 1.21 1.07 1.26 1.41
TA Atp5h
Mitochondrial
respiratory
chain
ATP synthase, H+
transporting,
mitochondrial F0
complex, subunit d
1.23 1.06 1.26 1.47
TA Cox6b1
Mitochondrial
respiratory
chain
cytochrome c
oxidase, subunit
VIb polypeptide 1
1.54 1.39 1.82 2.16
TA Cox6b2
Mitochondrial
respiratory
chain
cytochrome c
oxidase, subunit
VIb polypeptide 2
1.35 1.08 1.37 1.59
TA Cox7a1
Mitochondrial
respiratory
chain
cytochrome c
oxidase, subunit
VIIa 1
x 1.37 −1.52 1.45 1.98
TA Cox7b
Mitochondrial
respiratory
chain
cytochrome c
oxidase, subunit
VIIb
x 1.96 1.33 1.87 2.15
TA Ndufa1
Mitochondrial
respiratory
chain
NADH
dehydrogenase
(ubiquinone) 1
alpha subcomplex,
1
x 1.44 1.13 1.42 1.52
TA Ndufa1
Mitochondrial
respiratory
chain
NADH
dehydrogenase
(ubiquinone) 1
alpha subcomplex,
1
1.35 1.09 1.31 1.46
TA Uqcrb
Mitochondrial
respiratory
chain
ubiquinol-
cytochrome c
reductase binding
protein
x 1.81 1.40 1.82 2.14
TA Uqcrfs1
Mitochondrial
respiratory
chain
ubiquinol-
cytochrome c
reductase, Rieske
iron-sulfur
polypeptide 1
1.57 1.24 1.87 2.25
TA Uqcrh
Mitochondrial
respiratory
chain
ubiquinol-
cytochrome c
reductase hinge
protein
1.89 1.43 1.81 1.97
TA Uqcrh
Mitochondrial
respiratory
chain
ubiquinol-
cytochrome c
reductase hinge
protein
1.65 1.28 1.57 1.83
TA Fntb Steroid
biosynthesis
farnesyltransferase,
CAAX box, beta x 1.48 1.43 1.55 1.49
LH m g c s 2 Steroid
biosynthesis
3-hydroxy-3-
methylglutaryl-
Coenzyme A
synthase 2
x −1.32 −1.09 −1.28 −1.37
TA Agpat3 Triglyceride
1-acylglycerol-3-
phosphate
O-acyltransferase 3
x 1.81 1.31 1.65 2.0712 PPAR Research
Table 3: Continued.
Tissues Gene
name Function Sequence
description PPRE db/+ RSG 10MK RSG 30MK RSG 100MK
TA Aco1
Tricarboxylic
acid cycle (mit
oxidation)
aconitase 1 x 1.77 1.37 1.70 1.94
TA Aco2
Tricarboxylic
acid cycle (mit
oxidation)
aconitase 2,
mitochondrial x 1.38 1.18 1.66 1.98
TA Aldh5a1
Tricarboxylic
acid cycle (mit
oxidation)
aldhehyde
dehydrogenase
family 5, subfamily
A1
x 1.60 1.33 1.65 1.69
TA Dlst
Tricarboxylic
acid cycle (mit
oxidation)
dihydrolipoamide
S-
succinyltransferase
(E2 component of
2-oxo-glutarate
complex)
x 1.43 1.16 1.63 1.83
TA Fh1
Tricarboxylic
acid cycle (mit
oxidation)
fumarate hydratase
1 x 1.56 1.28 1.63 1.87
TA Idh3b
Tricarboxylic
acid cycle (mit
oxidation)
isocitrate
dehydrogenase 3
(NAD+), beta
x 1.49 1.18 1.73 1.91
TA Idh3g
Tricarboxylic
acid cycle (mit
oxidation)
isocitrate
dehydrogenase 3
(NAD+), gamma
x 1.67 1.18 1.59 1.91
TA Mdh1
Tricarboxylic
acid cycle (mit
oxidation)
malate
dehydrogenase 1,
NAD (soluble)
1.93 1.17 1.91 1.95
TA Mdh1
Tricarboxylic
acid cycle (mit
oxidation)
malate
dehydrogenase 1,
NAD (soluble)
1.63 1.44 2.01 2.17
TA Sdhb
Tricarboxylic
acid cycle (mit
oxidation)
succinate
dehydrogenase
complex, subunit
B, iron sulfur (Ip)
1.60 1.21 1.67 1.97
TA Sdhc
Tricarboxylic
acid cycle (mit
oxidation)
succinate
dehydrogenase
complex, subunit
C, integral
membrane protein
x 1.32 1.10 1.35 1.48
TA Sdhd
Tricarboxylic
acid cycle (mit
oxidation)
succinate
dehydrogenase
complex, subunit
D, integral
membrane protein
x 1.29 1.11 1.57 1.90
respiration and tricarboxylic acid cycle (Table 3)a n d3
out of 4 genes from liver are involved in gluconeogenesis.
Finally, among the 32 unique genes (corresponding to the
40 gene sequences), 21 presented a PPRE in their promoter
regulatory sequences.
These observations underline the link between RSG-
mediated PPARγ activation and expression of genes involved
in IAT mitochondrial function, liver gluconeogenesis, and
regulation of blood glucose.
4. Discussion
In this paper, for the ﬁrst time we have attempted to establish
a link between metabolic status of RSG-treated diabetic
mice (db/db) and RSG-mediated transcriptomic changes in
the three major insulin-dependent tissues including liver,
adipose tissue, and skeletal muscle.
As expected, numerous genes regulated by RSG and
identiﬁed in this study fall into key metabolic pathways
involved in carbohydrate and lipid metabolism. PPARγPPAR Research 13
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Figure 6: Expression proﬁles of key genes involved in Soleus muscle glucose and lipid metabolism. Diﬀerentially expressed genes in db/+
(the white square) and 10 (the oﬀ-white square), 30 (the grey square), and 100 (the black square) mg/kg RSG-treated db/db mice were
measured versus untreated db/db and plotted as the mean (% increase/decrease of db/db control) ±SEM (n = 6). NS; P ≥ .001 otherwise
P<. 001. (a) Genes related to glucose metabolism∗: Eno3, enolase 3, beta muscle; Hk1, hexokinase 1; Pkm2, pyruvate kinase, muscle;
Pgm2, phosphoglucomutase 2; Pygm, muscle glycogen phosphorylase. (b) Genes related to lipid metabolism: Dgat2, diacylglycerol O-
acyltransferase 2; Lipe, lipase hormone sensitive; ∗gene abbreviations given in Figures 1,a n d4 were not mentioned.
agonist also regulates many more genes in adipose tissue
than in liver or skeletal muscle, as might be expected, based
on PPARγ expression levels in the respective tissues. Despite
this diﬀerence, our data showed that PPARγ activation has
coordinated eﬀects on fundamental metabolic pathways in
each of these tissues, including glucose and lipid metabolism
in skeletal muscle, gluconeogenesis in liver, as well as
lipogenesis, TG storage, and mitochondrial function in
adipose tissue. Gene transcription modulation by RSG could
be classiﬁed into two types, namely, those which counteract
diabetes-inducedalterationandcorrelatedtothemodulation
observed in db/+ versus db/db and those which accentuate
diabetes induced alteration and are inversely correlated. The
ﬁrst group could explain the glucose and lipid-lowering
actions of PPARγ agonists, and the second group could be
linked to TZDs compound-mediated side eﬀects.
4.1. Liver. One of the most interesting observations is that
RSG treatment normalised glucose homeostasis in db/db
mice (result presented here in and in [15]) and the mRNA
expression of gluconeogenic key enzymes such as the G6pc,
Fbp1, and the glucose transporter Glut-2. These results
suggest that transcriptional regulation of G6pc and Fbp1
mRNA play a role in RSG-mediated decreased gluconeoge-
nesis and blood glucose normalisation. This observation is
in agreement with previous studies showing an increase in
G6pc and Fbp1 activities in db/db mice and the subsequent
increase in glucose production by the db/db liver [25].
In human, hepatic gluconeogenesis is known to be
signiﬁcantly enhanced in type 2 diabetes and normalised
by RSG [10, 26]. Therefore, the transcriptional status of
G6Pc and Fbp1, related to RSG-mediated gluconeogenesis
normalisation,deservestobefurtherinvestigatedinhumans.
In rodents one of the thiazolidinedione treatment side
eﬀects is associated with liver dysfunction. RSG-treated
db/db mice have shown a rise in their liver weight and
steatosis appearance, as previously shown [12]. Indeed, the
potent antihyperglycaemic eﬀect of RSG was accompanied
by an increase of de novo synthesis of fatty acids when
compared to either db/+ or db/db. Lipid metabolome
analysis was concordant with our gene expression proﬁling
obtained in liver and corroborate with the results obtained
in a previous study [13] .Ar i s ei nh e p a t i ce x p r e s s i o no f
genes belonging to numerous steps of the TG synthesis in
liver was observed under RSG treatment including those
that encode for FA transporters (Lpl, Cd36, Fabp2, 4),
TG (Gpd1) and FFA synthesis (Acly, Fasn, Acaca, Gpd1,
Agpat2, 6, Scd1) and are likely associated to the RSG-
mediated increase in hepatic trioleate levels. This result is
in contrast with the RSG eﬀects in humans and normal
mice,wherechronicRSGtreatmentreducedliverfat[27,28].
However db/db is a leptin signalling deﬁcient paradigm, and
numerous publications demonstrated in wild-type mice that
leptin decreases hepatic de novo synthesis of FA through the
decrease in mRNA, proteins, or enzymatic activities of FFA
andTGmetabolismenzymesincluding Acly,Acaca,Fas,Scd-
1, or Agpat [29–33]. Therefore, mice lacking leptin signalling
are not the best paradigm to foresee PPAR agonist secondary
eﬀects in human liver.
4.2. Inguinal Adipose Tissue. In adipose tissue, mitochondria
are not only the major site of fatty acid oxidation but
may also play a critical role in lipogenesis by providing
key intermediates for TG synthesis. Impaired mitochondria
may lead to the lack of ATP and subsequent reduction in
lipid metabolism [23]. This dysfunction could be linked
to a reduced ability of glucose utilization, participating
in high blood glucose levels in diabetic mice. A decrease
in ATP may also impair the synthesis and secretion of
adipokines, which were previously shown to be associated
with diabetes [34]. In our study, RSG signiﬁcantly induced a
dose-dependent increase in a number of genes implicated in14 PPAR Research
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Figure 7: Generation of PLS models to predict physiological changes from multivariate gene expression data. Results show the correlations
between the actual liver weight (a), the liver trioleate concentrations (b), the blood glucose level (c) and the predicted parameters from
the PLS model. The normalised logs (ratio) of genes involved in glucose and lipid metabolism were used as predictor variables (X) and
physiological parameters as response variables (Y). All variables were centred and scaled to unit variance, before the PLS analysis was
performed.
mitochondrial activities. Genes encoding for enzymes
involved in β-oxidation, citrate cycle, and oxidative phos-
phorylation were upregulated in a similar manner to that
observed in db/+ versus db/db mice. Moreover, we have
observed an upregulation of PPARγ coactivator PGC1α
(data not shown), which is known to potently activate
mitochondrial biogenesis in adipose and muscle tissues
[24, 35]. Combined with immunocytochemistry results,
these data showed that RSG treatment led to an increase
in mitochondrial biogenesis. The eﬀects of PPARγ agonist
on both mitochondrial number and morphology were
previously observed in adipose tissues of rat and dog treated
with RSG [36]. RSG is also known to induce adipocyte
diﬀerentiation and mitochondrial biogenesis [37]. These
new small adipocytes are insulin sensitive and possess
a higher lipid metabolism capacity that could explain the
RSG-increased mRNA of genes involved in lipid transport
and oxidation. The IAT is composed of both brown adipose
tissue (BAT) and white adipose tissue (WAT). Our data
show the upregulation of BAT markers Ucp1 or Cpt1b
in IAT of treated mice, as described by others [34]. This
observation supports the view of RSG converting WAT to
BAT, transforming IAT into fat-oxidizing machinery. They
alsosuggestthatdecreasingtheexposureofperipheraltissues
to lipids may improve the whole-body insulin sensitivity.
4.3. Soleus Muscle. Normalisation of hyperglycaemia by
RSG-decreased hepatic glucose synthesis and output seems
t ob ec o m b i n e dw i t hb e t t e ru s eo fg l u c o s ei ns o l e u sm u s c l e .PPAR Research 15
Indeed, RSG-treated mice showed an increased expression
of genes coding for key enzymes involved in glycolysis,
like Hexokinase1 Hk1, Enolase Eno3, or Pyruvate kinase
Pkm2, similar to our observation in db/+ versus db/db. RSG
treatment of db/db also resulted in a coordinated decrease
in the expression of some genes involved in fatty acid
transport and metabolism in muscle. It is noteworthy that
the expression of these genes was upregulated in liver and
to a lesser extent in IAT in response to RSG, suggesting that
PPARγ activation promotes a ﬂux of fatty acids into hepatic
and adipose tissues and away from muscle. Altogether,
these data suggest a decreased reliance on fatty acids and
an increased reliance on glucose as an energy source in
muscle, as previously described [2, 38]. Surprisingly, the
RSG-mediated gene expression normalisation in muscular
cells was observed mainly at 10mg/kg dose, whereas the
highest doses induced the expression of genes related to
glucose and lipid pathways in opposite direction to that
measuredindb/+ versusdb/db, suggestingapossible adverse
eﬀect at higher drug concentrations in this tissue.
4.4. PLS Models. Taking advantage of the experimental
design including both transcriptomic and metabolomic
approaches, we applied a multivariate linear regression
model (PLS) in order to predict the metabolic parameters
(i.e., blood glucose and FFA and TG from blood and tissues)
based on regulated genes (predictor (X) variables). Only
the variables X from liver allowed us to derive models
that signiﬁcantly predicted some of the measured biological
parameters such as liver oleic acid and trioleate as well as
the liver weight. It is worth noticing that among the 40
best predictors 20 (16 genes) are common between trioleate
and the liver weight model. The fact that among these 16
genes 13 display a PPRE and therefore are supposed to be
regulated by PPAR agonist reinforces the predictory status
of these 20 gene sequences. Obviously more experiments
should be undertaken with diﬀerent RSG dose treatments
to conﬁrm these predictors. Moreover, no signiﬁcant model
could be built with diﬀerential gene expression data from
liverandbloodmetabolicparameters,andnomodelcouldbe
obtainedwithIATorsoleusmuscleregardingbothtissueand
blood metabolic parameters. However, the most interesting
observation is that a model was validated with blood glucose
levels and the combination of gene expression data from
the 3 tissues. When looking at the 40 best predictors, we
found that a large majority of gene sequences implied IAT-
expressed genes (35/40), and among the 35, 25 encoded
mitochondrial proteins involved in energy cell production
and 4 gene sequences were originated from the liver and are
involved in gluconeogenesis. In that case we may hypothesise
that those blood glucose predictors are linked to molecular
mechanismsbecause;(i)mitochondrialdysfunctionislinked
to diabetes type 2 and thiazolidinediones were known to
improve the diabetes status by the production of more
functional adipocytes; (ii) in db/db mice high levels of blood
glucose partially is due to gluconeogenesis [25]a n dR S G
by decreasing mRNA encoding gluconeogenic enzymes may
indeed regulate blood glucose.
Therefore, PLS reveals not only IAT/liver predictors for
blood glucose regulation but also a potential molecular
mechanism that could explain in part the glucose regulation.
Whether or not this mechanism is due to direct PPARγ-
induced transcriptional eﬀects or PPAR interaction with
the mitochondrial protein such as MitoNEET [39] that
subsequently activate mitochondrial functions remains to be
investigated, but a majority of genes in the top 40 predictor
sequences (21/32 genes) displayed predicted PPRE in their
respective promoter.
5. Conclusion
To our knowledge, this is the ﬁrst study comparing gene
expression proﬁles between db/+ and RSG-treated db/db
with control diabetic db/db in liver, muscle, and adipose tis-
sues. The combination of transcriptomic and metabolomic
approaches led to a comprehensive molecular portrait and
hypothesis on the dose-dependent eﬀects of RSG in db/db
diabeticmiceandhighlightstheroleoftherespectiveinsulin-
dependent tissues. This approach could be useful in the
future to discriminate between selective PPAR modulators
regarding their speciﬁc molecular proﬁles in relation to
speciﬁc target tissues.
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